LXRX - Lexicon Pharmaceuticals Inc

-

$undefined

N/A

(N/A)

Lexicon Pharmaceuticals Inc NASDAQ:LXRX Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications.

Location: | Website: www.lexpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

199.4M

Cash

258.4M

Avg Qtr Burn

N/A

Short % of Float

18.39%

Insider Ownership

1.15%

Institutional Own.

81.95%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INPEFA™ (SOTAGLIFLOZIN) Details
Heart disease, Heart failure

Approved

Quarterly sales

XERMELO® (telotristat ethyl) Details
Carcinoid syndrome diarrhea

Approved

Quarterly sales

ZYNQUISTA™ (sotagliflozin) Details
Hypertrophic cardiomyopathies

Phase 3

Data readout

LX9211 Details
Neuropathy, Diabetic peripheral neuropathy

Phase 2b

Data readout

LX9851 Details
Obesity, Cardiovascular disease

IND

Submission

ZYNQUISTA™ (sotagliflozin) Details
Type 1 diabetes, Diabetes

Failed

Discontinued